Esperion Therapeutics Cash Flow - Annual (NASDAQ:ESPR)

Add to My Stocks
$36.69 $0.69 (1.85%) ESPR stock closing price Apr 21, 2017 (Closing)

The Esperion Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. While its important to look at the Esperion Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Esperion Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Esperion Therapeutics stock analysis shows negative net income cash flow of $-74.97M for 2016. This statement is important because profits alone cannot pay employees, or bills. Cash is required.   Esperion Therapeutics had an outflow of $9.58M from operating activities, $192.07M spend due to financing activities, and $170.17M gain due to investing activities for 2016. View details of Esperion Therapeutics cash flows for latest & last ten financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011
Esperion Therapeutics Net Income Cash Flow
-74.97M-49.78M-36.37M-26.08M-11.74M-10.81M
Depreciation Depletion Amortization Cash-Flow1.31M0.94M0.39M0.59M0.27M0.17M
Net Increase (Decrease) in Assets Liabilities9.98M-2.08M0.25M3.22M-0.84M0.8M
Cash From (used in) Discontinued Operations------
Other Adjustments Net15.95M12.77M3.71M4.15M0.04M0.08M
Esperion Therapeutics Net Cash from (used by) Operating Activities
-47.73M-38.15M-32.02M-18.11M-10.8M-9.06M
Increase (Decrease) in Prop Plant And Equipment-0.09M-0.3M-0.86M0.16M-0.01M
Acquisition Disposition of Subsidiaires------
Increase (Decrease) in Investments10.21M-159.76M-35.73M-21.17M-0.5M
Other Cash Inflow (Outflow) from Investment Activities------
Esperion Therapeutics Net Cash from (used by) Invesment Activities
10.11M-160.06M-36.59M-21M-0.5M
Issuance (Purchase) of Equity Shares0.04M191.16M92.28M89.14M0.04M6.71M
Issuance (Repayment) of Debt Securities-1.6M-0.63M4.83M-15.41M-
Increase (Decrease) in Bank & Other Borrowings------
Payment of Dividends & Other Cash Distributions------
Other Cash from (used by) Financing Activities
Esperion Therapeutics Net Cash from (used by) Financing Activities
-1.55M190.52M97.12M89.14M15.75M6.71M
Effect of Exchange Rate Changes on Cash------
Esperion Therapeutics Net Change in Cash & Cash Equivalents
-39.17M-7.7M28.5M50.02M4.94M-1.84M
Cash & Equivalents at Beginning of Year77.33M85.03M56.53M6.51M1.57M3.41M
Cash & Equivalents at Year End38.16M77.33M85.03M56.53M6.51M1.57M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

Esperion Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Esperion Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:
  • Esperion Therapeutics saw a decrease in Net Change in Cash and Cash Equivalents from $-7.7M in 2015 to $-39.17M in 2016. Apart from the Esperion Therapeutics stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-47.73M for ESPR.
  • Cash from investing stood at a positive value of $10.11M for ESPR stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-1.55M for Esperion Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.
.